Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer

Oncotarget

Volumn 8, Issue 6, 2017, Pages 9293-9302

  Zhao, Ren ^a   Cai, Zhen ^b   Li, Sheng ^b   Cheng, Yong ^c   Gao, Hua ^d   Liu, Fang ^e   Wu, Shiyang ^e   Liu, Suyan ^e   Dong, Yan ^e   Zheng, Lei ^b   Zhang, Wenbin ^d   Wu, Xiaojun ^f   Yao, Xueqing ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e SurExam Bio Tech Co Ltd   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Circulating tumor cells; Clinical stage; Colorectal cancer; Epithelial mesenchymal transition; Metastasis

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; PROTEIN KINASE B BETA; PROTEIN SNAI1; TWIST RELATED PROTEIN 1; UNCLASSIFIED DRUG; VIMENTIN; CELL FREE NUCLEIC ACID; TUMOR MARKER;

ARTICLE; BIOPHENOTYPIC CIRCULATING TUMOR CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CIRCULATING TUMOR CELL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; EPITHELIAL CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL CIRCULATING TUMOR CELL; MOLECULAR DYNAMICS; PHENOTYPE; PROTEIN EXPRESSION; VALIDATION PROCESS; BLOOD; CHEMISTRY; CHINA; COLORECTAL TUMOR; FLUORESCENCE MICROSCOPY; GENETICS; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CELL-FREE NUCLEIC ACIDS; CHINA; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IN SITU HYBRIDIZATION; LYMPHATIC METASTASIS; MICROSCOPY, FLUORESCENCE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 85011954008     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14065     Document Type: Article

References (44)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25:iii1-iii9.
3. Zlobec I. Novel biomarkers for the prediction of metastasis in colorectal cancer. Expert Opin Med Diagn. 2013; 7:137-146.
4. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10:6897-6904.
5. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19:935-938.
6. Gazzaniga P, Gianni W, Raimondi C, Gradilone A, Lo Russo G, Longo F, Gandini O, Tomao S, Frati L. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumor Biol. 2013; 34:2507-2509.
7. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M, Weitz J. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010; 138:1714-1726.
8. Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer-a review. Eur J Surg Oncol (EJSO). 2011; 37:459-465.
9. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, et al. Relationship of circulating tumor cells to tumor response, progressionfree survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:3213-3221.
10. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20:1223-1229.
11. Koerkamp BG, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013; 20:2156-2165.
12. Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. The Oncologist. 2012; 17:947-955.
13. Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Cohen SJ. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013; 24:420-428.
14. Matsusaka S, Suenaga M, Mishima Y, Kuniyoshi R, Takagi K, Terui Y, Mizunuma N, Hatake K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2011; 102:1188-1192.
15. Gazzaniga P, Gradilone A, Petracca A, Nicolazzo C, Raimondi C, Iacovelli R, Naso G, Cortesi E. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med. 2010; 14:2073-2077.
16. Abdallah EA, Fanelli MF, Buim ME, Machado Netto MC, Gasparini Junior JL, Souza E Silva V, Dettino AL, Mingues NB, Romero JV, Ocea LM, Rocha BM, Alves VS, Araújo DV, et al. Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer. 2015; 137:1397-1405.
17. Pantel K, BrakenhoffRH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4:448-456.
18. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138.
19. Barrière G, Tartary M, Rigaud M. Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol. 2012; 2012:382010.
20. Liu H, Zhang X, Li J, Sun B, Qian H, Yin Z. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol. 2015; 141:189-201.
21. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994; 125:437-446.
22. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Brit J Cancer. 2010; 103:382-390.
23. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004; 37:529-540.
24. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68:3033-3046.
25. Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene. 2010; 29:3173-3184.
26. Gomez I, Peña C, Herrera M, Muñoz C, Larriba MJ, Garcia V, Dominguez G, Silva J, Rodriguez R, Garcia de Herreros A, Bonilla F, Garcia JM. TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS One. 2011; 6:e18023.
27. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, Evers BM. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci. 2008; 105:20315-20320.
28. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24:7443-7454.
29. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM. Overexpression of Snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012; 1:5-16.
30. Min AL, Choi JY, Woo HY, Kim JD, Kwon JH, Bae SH, Yoon SK, Shin SH, Chung YJ, Jung CK. High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin Exp Metastasis. 2009; 26:759-767.
31. Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng L, Zuo GH, Huang XB, Li HY, Zhao HZ, Yu ZP, Zhou Z, Liang P. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis. 2013; 4:e831.
32. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, IsakoffSJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339:580-584.
33. Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015; 5:155.
34. Grosse-Wilde A, Fouquier d'Hérouël A, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, del Sol A, Walters KA, Huang S. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One. 2015; 10:e0126522.
35. Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016. Oncotarget. 2016;7:27067-84. doi: 10.18632/oncotarget.8166.
36. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015; 21:899-906.
37. Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One. 2015; 10:e0123976.
38. Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, Thierry B. Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress. Mol Med. 2015; 21:S25-S31.
39. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normallike breast tumor cells. J Natl Cancer Inst. 2009; 101:61-66.
40. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011; 50:700-710.
41. Thorsteinsson M, Söletormos G, Jess P. Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 2011; 31:613-617.
42. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, KaifiJT, Belani CP, Truica CI, El-Deiry WS, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014; 60:323-333.
43. Lim SH, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014; 67:848-853.
44. Dexter DL, Spremulli EN, Fligiel Z, Barbosa JA, Vogel R, VanVoorhees A, Calabresi P. Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med. 1981; 71:949-956.